{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:54Z","timestamp":1781646714708,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diffuse Pleural Mesothelioma (DPM) is an aggressive cancer with limited treatment options and a poor prognosis. Maintenance therapy has emerged as a potential strategy to delay disease progression following first-line chemotherapy. This study evaluates the efficacy and safety of gemcitabine maintenance therapy compared to best supportive care (BSC) in patients with unresectable DPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center, randomized, phase II, open-label trial included 64 patients with unresectable DPM who achieved a complete\/partial response or stable disease after first-line platinum-based chemotherapy. They were randomized 1:1 to receive gemcitabine maintenance therapy (GEM group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932) or BSC (BSC group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932). Progression-free survival (PFS) was the primary endpoint, while overall survival (OS) and toxicity were secondary endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Gemcitabine maintenance therapy significantly improved PFS (median: 6.2 months vs. 2.8 months; HR: 4.33, 95% CI: 2.48\u20137.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, no significant difference in OS was observed between the GEM and BSC groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.155). Performance status (PS) at randomization and histological type were significant prognostic factors for survival. The GEM group experienced higher rates of hematological toxicities, while the BSC group reported more dyspnea, fatigue, and chest pain. No grade 3 or 4 toxicities were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gemcitabine maintenance therapy effectively delays disease progression in patients with unresectable DPM, with a manageable toxicity profile. However, its impact on OS is limited. Performance status and histological type remain critical factors in predicting treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (ID NCT07411144, Date 1322026).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15836-3","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:29:40Z","timestamp":1774513780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohamed Emam","family":"Sobeih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Helal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Yahia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Khorshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"15836_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:129\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005.","journal-title":"Ann Oncol"},{"key":"15836_CR2","unstructured":"Cancer Today. [cited 2025 June 4]. https:\/\/gco.iarc.who.int\/today\/. Accessed 4 June 2025."},{"key":"15836_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(15)01238-6.","journal-title":"Lancet"},{"key":"15836_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","volume":"12","author":"E Lim","year":"2024","unstructured":"Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respiratory Med Elsevier. 2024;12:457\u201366. https:\/\/doi.org\/10.1016\/S2213-2600(24)00119-X.","journal-title":"Lancet Respiratory Med Elsevier"},{"key":"15836_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"key":"15836_CR6","doi-asserted-by":"publisher","first-page":"100323","DOI":"10.1016\/j.opresp.2024.100323","volume":"6","author":"R L\u00f3pez-Castro","year":"2024","unstructured":"L\u00f3pez-Castro R, Fuentes-Mart\u00edn \u00c1, Medina del Valle A, Garc\u00eda Pe\u00f1a T, Soro Garc\u00eda J, L\u00f3pez Gonz\u00e1lez L, et al. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights. Open Respiratory Archives. 2024;6:100323. https:\/\/doi.org\/10.1016\/j.opresp.2024.100323.","journal-title":"Open Respiratory Archives"},{"key":"15836_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074.","journal-title":"Ann Oncol"},{"key":"15836_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1343\u201373. https:\/\/doi.org\/10.1200\/JCO.2017.76.6394.","journal-title":"J Clin Oncol"},{"key":"15836_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"L de Sousa Cavalcante","year":"2014","unstructured":"de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8\u201316. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.041.","journal-title":"Eur J Pharmacol"},{"key":"15836_CR10","doi-asserted-by":"crossref","unstructured":"Burgers SA, de Gooijer C, Cornelissen R, Aerts JG, Biesma B, Heemst RV et al. Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: 44th Congress of the European-Society-for-Medical-Oncology (ESMO). Ann Oncol. 2019;30.","DOI":"10.1093\/annonc\/mdz394.092"},{"key":"15836_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/pros.23236","volume":"76","author":"R Cathomas","year":"2016","unstructured":"Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, et al. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08\/11). Prostate. 2016;76:1519\u201327. https:\/\/doi.org\/10.1002\/pros.23236.","journal-title":"Prostate"},{"key":"15836_CR12","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/cncr.30170","volume":"122","author":"J-M Ferrero","year":"2016","unstructured":"Ferrero J-M, Hardy-Bessard A-C, Capitain O, Lortholary A, Salles B, Follana P, et al. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Cancer. 2016;122:3119\u201326. https:\/\/doi.org\/10.1002\/cncr.30170.","journal-title":"Cancer"},{"key":"15836_CR13","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1093\/annonc\/mdw416","volume":"27","author":"S Kanda","year":"2016","unstructured":"Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol. 2016;27:2242\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdw416.","journal-title":"Ann Oncol"},{"key":"15836_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jtho.2016.03.007","volume":"11","author":"S Kulkarni","year":"2016","unstructured":"Kulkarni S, Vella ET, Coakley N, Cheng S, Gregg R, Ung YC, et al. The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review. J Thorac Oncol. 2016;11:989\u20131002. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.007.","journal-title":"J Thorac Oncol"},{"key":"15836_CR15","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375:2154\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1611310.","journal-title":"N Engl J Med"},{"key":"15836_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2217\/fon-2015-0065","volume":"12","author":"S Rossi","year":"2016","unstructured":"Rossi S, Schinzari G, Basso M, Strippoli A, Dadduzio V, D\u2019Argento E, et al. Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. Future Oncol. 2016;12:1299\u2013307. https:\/\/doi.org\/10.2217\/fon-2015-0065.","journal-title":"Future Oncol"},{"key":"15836_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/15384047.2016.1195049","volume":"17","author":"M Zwitter","year":"2016","unstructured":"Zwitter M, Rajer M, Stanic K, Vrankar M, Doma A, Cuderman A, et al. Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Cancer Biol Ther. 2016;17:833\u20139. https:\/\/doi.org\/10.1080\/15384047.2016.1195049.","journal-title":"Cancer Biol Ther"},{"key":"15836_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","volume":"14","author":"WA Buikhuisen","year":"2013","unstructured":"Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FMNH, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013;14:543\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(13)70125-6.","journal-title":"Lancet Oncol"},{"key":"15836_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019;37:790\u20138. https:\/\/doi.org\/10.1200\/JCO.2018.79.0543.","journal-title":"J Clin Oncol"},{"key":"15836_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","volume":"8","author":"RA Belderbos","year":"2019","unstructured":"Belderbos RA, Baas P, Berardi R, Cornelissen R, Fennell DA, van Meerbeeck JP, et al. A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl Lung Cancer Res. 2019;8:280\u20135. https:\/\/doi.org\/10.21037\/tlcr.2019.05.05.","journal-title":"Transl Lung Cancer Res"},{"key":"15836_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","volume":"21","author":"AZ Dudek","year":"2020","unstructured":"Dudek AZ, Wang X, Gu L, Duong S, Stinchcombe TE, Kratzke R, et al. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020;21:553\u2013e5611. https:\/\/doi.org\/10.1016\/j.cllc.2020.06.025.","journal-title":"Clin Lung Cancer"},{"key":"15836_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","volume":"9","author":"CJ de Gooijer","year":"2021","unstructured":"de Gooijer CJ, van der Stigt NV, Baas JA, Biesma P, Cornelissen B. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respiratory Med Elsevier. 2021;9:585\u201392. https:\/\/doi.org\/10.1016\/S2213-2600(20)30362-3.","journal-title":"Lancet Respiratory Med Elsevier"},{"key":"15836_CR23","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1080\/14796694.2025.2516412","volume":"21","author":"AS Karam","year":"2025","unstructured":"Karam AS, Abdelwahab S, Ezz El Din MMA, Alorabi MO. A randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma. Future Oncol. 2025;21:2203\u201313. https:\/\/doi.org\/10.1080\/14796694.2025.2516412.","journal-title":"Future Oncol"},{"key":"15836_CR24","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22:1438\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00404-6.","journal-title":"Lancet Oncol"},{"key":"15836_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10147-025-02706-4","volume":"30","author":"M Kanayama","year":"2025","unstructured":"Kanayama M, Manabe T, Yoshimatsu K, Oyama R, Matsumiya H, Mori M, et al. Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data. Int J Clin Oncol. 2025;30:705\u201317. https:\/\/doi.org\/10.1007\/s10147-025-02706-4.","journal-title":"Int J Clin Oncol"},{"key":"15836_CR26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","volume":"31","author":"S Popat","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O\u2019Brien M, Pope A, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial. Annals Oncol Elsevier. 2020;31:1734\u201345. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.009.","journal-title":"Annals Oncol Elsevier"},{"key":"15836_CR27","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol Elsevier. 2021;22:1530\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(21)00471-X.","journal-title":"Lancet Oncol Elsevier"},{"key":"15836_CR28","doi-asserted-by":"publisher","first-page":"e0149247","DOI":"10.1371\/journal.pone.0149247","volume":"11","author":"X Hu","year":"2016","unstructured":"Hu X, Pu K, Feng X, Wen S, Fu X, Guo C, et al. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE. 2016;11:e0149247. https:\/\/doi.org\/10.1371\/journal.pone.0149247.","journal-title":"PLoS ONE"},{"key":"15836_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/CAD.0000000000001079","volume":"32","author":"K Hamai","year":"2021","unstructured":"Hamai K, Fujitaka K, Kitaguchi S, Tamamoto S, Takao S, Nishida A, et al. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB\/IV squamous cell lung cancer: a phase II study. Anticancer Drugs. 2021;32:767\u201372. https:\/\/doi.org\/10.1097\/CAD.0000000000001079.","journal-title":"Anticancer Drugs"},{"key":"15836_CR30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/iju.12727","volume":"22","author":"S Muto","year":"2015","unstructured":"Muto S, Abe H, Noguchi T, Sugiura S, Kitamura K, Isotani S, et al. Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol. 2015;22:490\u20134. https:\/\/doi.org\/10.1111\/iju.12727.","journal-title":"Int J Urol"},{"key":"15836_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5152\/tud.2017.24478","volume":"43","author":"T Ku\u015f","year":"2017","unstructured":"Ku\u015f T, Akta\u015f G. Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. Turk J Urol. 2017;43:273\u20138. https:\/\/doi.org\/10.5152\/tud.2017.24478.","journal-title":"Turk J Urol"},{"key":"15836_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s10330-013-1259-y","volume":"12","author":"X Yin","year":"2013","unstructured":"Yin X, Ma H, Li X, Dai Z, Xue X, Zhang S, et al. The observation of single-agent gemcitabine maintenance therapy in patients with metastatic breast cancer. Chin -Ger J Clin Oncol. 2013;12:568\u201373. https:\/\/doi.org\/10.1007\/s10330-013-1259-y.","journal-title":"Chin -Ger J Clin Oncol"},{"key":"15836_CR33","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","volume":"30","author":"M P\u00e9rol","year":"2012","unstructured":"P\u00e9rol M, Chouaid C, P\u00e9rol D, Barl\u00e9si F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516\u201324. https:\/\/doi.org\/10.1200\/JCO.2011.39.9782.","journal-title":"J Clin Oncol"},{"key":"15836_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","volume":"52","author":"T Brodowicz","year":"2006","unstructured":"Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006;52:155\u201363. https:\/\/doi.org\/10.1016\/j.lungcan.2006.01.006.","journal-title":"Lung Cancer"},{"key":"15836_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jgo.2019.08.008","volume":"11","author":"R Petrioli","year":"2020","unstructured":"Petrioli R, Torre P, Pesola G, Paganini G, Paolelli L, Miano ST, et al. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. J Geriatr Oncol. 2020;11:647\u201351. https:\/\/doi.org\/10.1016\/j.jgo.2019.08.008.","journal-title":"J Geriatr Oncol"},{"key":"15836_CR36","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/annonc\/mdt123","volume":"24","author":"C Obasaju","year":"2013","unstructured":"Obasaju C, Bowman L, Wang P, Shen W, Winfree KB, Smyth EN, et al. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)\u2020. Ann Oncol. 2013;24:1534\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdt123.","journal-title":"Ann Oncol"},{"key":"15836_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.lungcan.2015.06.005","volume":"89","author":"F Zhou","year":"2015","unstructured":"Zhou F, Jiang T, Ma W, Gao G, Chen X, Zhou C. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis. Lung Cancer Elsevier. 2015;89:203\u201311. https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.005.","journal-title":"Lung Cancer Elsevier"},{"key":"15836_CR38","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/jco.2010.28.15_suppl.7506","volume":"28","author":"CP Belani","year":"2010","unstructured":"Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). JCO Wolters Kluwer. 2010;28:7506\u20137506. https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.7506.","journal-title":"JCO Wolters Kluwer"},{"issue":"Suppl 6","key":"15836_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00001813-199512006-00005","volume":"6","author":"M Tonato","year":"1995","unstructured":"Tonato M, Mosconi AM, Martin C. Safety profile of gemcitabine. Anticancer Drugs. 1995;6(Suppl 6):27\u201332. https:\/\/doi.org\/10.1097\/00001813-199512006-00005.","journal-title":"Anticancer Drugs"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15836-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15836-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15836-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:17Z","timestamp":1781643257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15836-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15836"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15836-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7905585\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each participant provided a written informed consent before enrollment after a complete explanation of the study protocol and its possible drawbacks and complications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"458"}}